Kong Xiangyi, Gong Shun, Yan Tao, Yang Yi
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, People's Republic of China,
Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People's Republic of China.
Cancer Manag Res. 2018 Aug 24;10:2825-2834. doi: 10.2147/CMAR.S171137. eCollection 2018.
To elucidate the clinical implication of microRNA (miRNA)-200b in the pathological grading of gliomas.
We searched the Chinese National Knowledge Infrastructure, Web of Knowledge, Embase, and PubMed databases. Related articles were assessed, and ORs with 95% CIs were calculated to examine the relationship between miRNA-200b expression levels and the World Health Organization (WHO) glioma grade, patients' sex and age, tumor size, and extent of surgical resection. Heterogeneity, publication bias, and stability of the pooled results of the included studies were also analyzed. MiR-200b expression in 87 human glioma tissues (50 high grade and 37 low grade) and matched 41 non-neoplastic brain tissues was measured by real-time quantitative RT-PCR assay.
Five eligible studies involving 630 patients were included in the present meta-analysis. The miRNA-200b expression in glioma tissues was negatively associated with the WHO glioma grade (OR, 0.070; 95% CI, 0.007-0.678; =0.022). No significant correlations were found between miRNA-200b and sex (=0.858), age (=0.776), tumor size (=0.134), or extent of resection (=0.778). In our own test, compared with non-neoplastic brain tissues, the expression level of miR-200b was significantly decreased in glioma tissues (tumor vs normal: 4.29±1.90 vs 10.45±2.34, <0.001). In addition, we found that the glioma tissues from high-grade tumors (grade III and IV) had much lower miR-200b expression than glioma tissues from low grade tumors (grade I and II).
Our results suggest that the miRNA-200 expression level may be negatively associated with the WHO glioma grade (malignancy). MiRNA-200 might serve as a prognostic and diagnostic biomarker or a helpful therapeutic target.
阐明微小RNA（miRNA）-200b在胶质瘤病理分级中的临床意义。
检索中国知网、Web of Knowledge、Embase和PubMed数据库。评估相关文章，并计算95%置信区间的比值比（OR），以研究miRNA-200b表达水平与世界卫生组织（WHO）胶质瘤分级、患者性别和年龄、肿瘤大小及手术切除范围之间的关系。还分析了纳入研究的合并结果的异质性、发表偏倚和稳定性。通过实时定量逆转录聚合酶链反应（RT-PCR）检测87例人类胶质瘤组织（50例高级别和37例低级别）及41例匹配的非肿瘤性脑组织中miR-200b的表达。
本荟萃分析纳入了5项涉及630例患者的合格研究。胶质瘤组织中miRNA-200b的表达与WHO胶质瘤分级呈负相关（OR，0.070；95%置信区间，0.007 - 0.678；P = 0.022）。未发现miRNA-200b与性别（P = 0.858）、年龄（P = 0.776）、肿瘤大小（P = 0.134）或切除范围（P = 0.778）之间存在显著相关性。在我们自己的检测中，与非肿瘤性脑组织相比，胶质瘤组织中miR-200b的表达水平显著降低（肿瘤组织与正常组织：4.29±1.90 vs 10.45±2.34，P < 0.001）。此外，我们发现高级别肿瘤（III级和IV级）的胶质瘤组织中miR-200b的表达远低于低级别肿瘤（I级和II级）的胶质瘤组织。
我们的结果表明，miRNA-200的表达水平可能与WHO胶质瘤分级（恶性程度）呈负相关。MiRNA-200可能作为一种预后和诊断生物标志物或一个有用的治疗靶点。
